Evidence map›Paper›PMID 30778774›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2019

The effectiveness of serum midkine in detecting esophageal squamous cell carcinoma.

Fumiaki Shiratori, Masaaki Ito, Satoshi Yajima, Takashi Suzuki, Yoko Oshima, Tatsuki Nanami, Kimihiko Funahashi, Hideaki Shimada

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Preoperative Low Serum Calcium Levels Predict Poor Prognosis for Patients with Esophageal Cancer.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Fumiaki ShiratoriDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Masaaki ItoDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Satoshi YajimaDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Takashi SuzukiDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Yoko OshimaDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Tatsuki NanamiDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Kimihiko FunahashiDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Hideaki ShimadaDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies investigating serum midkine (s-MK) concentrations have employed a polyclonal antibody enzyme-linked immunosorbent assay system (ELISA), because the targeted polyclonal antibody has low specificity. We used a newly developed monoclonal antibody ELISA to investigate the prognostic and diagnostic capabilities of s-MK in patients with esophageal squamous cell carcinoma.

methodsSerum samples from 102 patients with esophageal squamous cell carcinoma were analyzed using a newly developed monoclonal antibody ELISA specifically developed to detect s-MK. s-MK cutoff value was set at 421 pg/mL (mean + 2 SD) based on data from healthy controls. Clinicopathological characteristics, including tumor stage and positivity rates for two conventional tumor markers, serum p53 (s-p53-Abs) antibodies and SCC-antigen, were evaluated to assess a possible correlation with s-MK. The prognostic capability of a high s-MK level was evaluated using univariate and multivariate methods.

resultsOverall positive rate for s-MK concentrations: 21%. Large tumors (> 50 mm) showed significantly higher concentrations than smaller specimens, but other clinicopathological factors were not associated with s-MK. A combination assay using SCC-antigen together with s-p53-Abs and s-MK clearly increased our capability to detect esophageal squamous cell carcinoma. Although the difference was not statistically significant (P = 0.310), the high s-MK group experienced worse overall survival than our low s-MK group.

conclusionss-MK and conventional tumor marker combination increased our capability to detect esophageal squamous cell carcinoma. Although s-MK might be associated with esophageal squamous cell carcinoma progression, it was not an independent risk factor reducing patient survival. This study was registered as UMIN000014530.

Indexed as

AdultAgedAged, 80 and overAntibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorEnzyme-Linked Immunosorbent AssayEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleHumansMaleMiddle AgedMidkineNeoplasm StagingPrognosisAntibodies, MonoclonalAntigens, NeoplasmBiomarkers, TumorMDK protein, humanMidkineSerpinssquamous cell carcinoma-related antigenBiomarkerELISAEsophageal squamous cell carcinomaMidkineMonoclonal antibody

Identifiers

PMID30778774
OpenAlexW2915125826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.